Information Provided By: 
Fly News Breaks for November 13, 2018
AZN, PHAS
Nov 13, 2018 | 06:10 EDT
Needham analyst Chad Messer initiated PhaseBio (PHAS) with a Buy rating and a price target of $18, saying it poses an "attractive investment with a near term commercial opportunity from PB2452" - the closes to market threat to AstraZeneca's (AZN) Brilinta to treat orphan cardiopulmonary diseases. The analyst notes that the company is also evaluating PB1046, which is a "weekly injectable form of vasoactive intestinal peptide with a vastly increased half life over the natural form", for potential treatment of rare pulmonary arterial hypertension.
News For PHAS;AZN From the Last 2 Days
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
